Friends! In this video, I'm going to do a Pfizer stock analysis and talk about the risks and upside potential with PFE stock.
1 extracted signal · 0 resolved · 1 still active
The Patient InvestorIndependent analyst profile- Source published
- 22 Sept 2025, 22:36 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The analysis focuses on Pfizer (PFE), currently priced at $24.03. Over the past five years, the stock has seen a 29% decline. However, the dividend yield is currently at 7%, making it attractive given lower interest rates. The recent earnings report was positive, with earnings per share exceeding expectations (78 cents vs. 58 cents expected) and strong revenue growth. Oncology sector growth is highlighted. The analysis states new products see a 15% revenue increase. Guidance for 2025 is positive, raising EPS estimates from $2.80-$3.00 to $2.90-$3.10. The company aims to maintain and grow dividends, reinvest in R&D, and de-leverage its balance sheet, but has not been buying back stock to create value for shareholders. High debt levels, $6 billion due in 2026, are limiting buybacks. The expectation is that future debt will lower due to current management, which could change the strategy. Free cash flow yield is 11%, while the dividend payout ratio is 65-68%. The analysis expects a significant increase in free cash flow from $12 billion to $19 billion by 2027, while current revenues are in line with those estimated, which are expected to lower the company’s need to spend. The average historical P/E ratio is around 12.85, but is at 8.67.The stock may trade around 11-13% annually.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.